Jaguar Health, Inc.
JAGX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.04
KIRA · Stoqly’s AI analyst, in plain words
- Jaguar Health, Inc. had $11.5M of revenue in fiscal 2025, down 1.5% on the year before. Over five years, revenue changed +4.2% a year on average.
- Its operating margin was −398.8%, down 135.1 pts: of every 100 in sales, about −399 is left after running the business.
- Jaguar Health, Inc. lost $53.6M in fiscal 2025.
Market cap
$1.7M
P/E
0.0x
Revenue
$11.5M
Net income
−$53.6M
Free cash flow
—
Operating margin
−398.8%
Jaguar Health, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−1.5%
No. Sales fell 1.5% last year.
Does it make a profit?
−465.4%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What Jaguar Health, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 7, 2026
- Legal name
- Jaguar Health, Inc.
- CIK
- 0001585608
Jaguar Health, Inc. · JAGX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M |
| Revenue growth | −53.8% | 175.8% | −18.4% | 19.8% | −1.5% |
| Gross margin | 46.2% | 83.1% | 79.1% | 83.3% | 67.2% |
| Operating margin | −939.1% | −287.8% | −351.3% | −263.8% | −398.8% |
| Net income | −$0.1M | −$0.0M | −$0.0M | −$38.5M | −$53.6M |
| Net margin | −1.2% | −0.4% | −0.4% | −329.3% | −465.4% |
| Diluted EPS | −$88.22 | −$36.18 | −$2,678.17 | −$130.69 | −$22.97 |
| Cash | |||||
| Cash from operations | −$35.0M | −$33.1M | −$33.2M | −$29.4M | −$23.7M |
| Capital expenditure | $0.0M | $0.1M | — | $0.0M | — |
| Free cash flow | −$35.0M | −$33.2M | — | −$29.4M | — |
| FCF margin | −806.8% | −277.5% | — | −251.5% | — |
| Share count change | −95.4% | 120.0% | −98.8% | 1,812.3% | 692.0% |
| Debt and strength | |||||
| Cash and short-term investments | $17.1M | $5.5M | $6.5M | $8.0M | $1.0M |
| Shareholders' equity | $11.9M | −$1.4M | $4.9M | $6.5M | −$18.7M |
| Current ratio | 1.8x | 0.7x | 2.0x | 1.6x | 0.5x |
| Interest coverage | −4.8x | −2.7x | −5.4x | −133.5x | −685.2x |
| Returns and quality | |||||
| Return on equity | −0.4% | −0.9% | −2.4% | −675.8% | — |
| Piotroski F-score | 3 | 2 | 3 | 3 | 2 |
| Altman Z'' | −16.7 | −24.4 | −22.4 | −23.3 | −45.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jaguar Health, Inc. · JAGX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.04 a share, the company is worth $1.7M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001585608). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.